BR112017010303A2 - anticorpos anti-cd47, métodos e usos - Google Patents

anticorpos anti-cd47, métodos e usos

Info

Publication number
BR112017010303A2
BR112017010303A2 BR112017010303A BR112017010303A BR112017010303A2 BR 112017010303 A2 BR112017010303 A2 BR 112017010303A2 BR 112017010303 A BR112017010303 A BR 112017010303A BR 112017010303 A BR112017010303 A BR 112017010303A BR 112017010303 A2 BR112017010303 A2 BR 112017010303A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
significant
monoclonal antibodies
activity
Prior art date
Application number
BR112017010303A
Other languages
English (en)
Inventor
Pietsch Christine
Mimi Zhou Hong
Dong Jianying
Cardoso Rosa
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112017010303A2 publication Critical patent/BR112017010303A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente revelação refere-se, em geral, aos anticorpos monoclonais que especificamente se ligam ao cd47, mais especifica-mente, aos anticorpos anti-cd47 que não têm significativa atividade de agregação plaquetária e não têm significativa atividade de hemaglutinação. também são fornecidos métodos para gerar esses anticorpos e métodos para usar esses anticorpos monoclonais como agentes terapêuticos.
BR112017010303A 2014-11-18 2015-11-17 anticorpos anti-cd47, métodos e usos BR112017010303A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081134P 2014-11-18 2014-11-18
PCT/US2015/061014 WO2016081423A1 (en) 2014-11-18 2015-11-17 Cd47 antibodies, methods, and uses

Publications (1)

Publication Number Publication Date
BR112017010303A2 true BR112017010303A2 (pt) 2018-05-15

Family

ID=54705894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010303A BR112017010303A2 (pt) 2014-11-18 2015-11-17 anticorpos anti-cd47, métodos e usos

Country Status (15)

Country Link
US (1) US10864268B2 (pt)
EP (1) EP3221358B1 (pt)
JP (1) JP6857603B2 (pt)
KR (1) KR20170081699A (pt)
CN (1) CN107406503B (pt)
AU (1) AU2015350190B2 (pt)
BR (1) BR112017010303A2 (pt)
CA (1) CA2967379A1 (pt)
EA (1) EA201791093A1 (pt)
IL (1) IL252198A0 (pt)
MX (1) MX2017006485A (pt)
PH (1) PH12017500915A1 (pt)
SG (1) SG11201704058TA (pt)
WO (1) WO2016081423A1 (pt)
ZA (1) ZA201704117B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
US11649284B2 (en) * 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
CA3040440C (en) * 2016-07-15 2022-12-13 Korea Institute Of Science And Technology A novel nanocage and use thereof
WO2018075857A1 (en) * 2016-10-20 2018-04-26 I-Mab Novel cd47 monoclonal antibodies and uses thereof
EP3534965A4 (en) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS
US11401329B2 (en) * 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
CA3072998A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited Binding agents
WO2019099852A1 (en) * 2017-11-17 2019-05-23 University Of Massachusetts Humanized 2c7 monoclonal antibody directed against a neisseria gonorrhoeae lipooligosaccharide (los) epitope, for human use
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
GB201804860D0 (en) * 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
US11634490B2 (en) 2018-06-15 2023-04-25 Accurus Biosciences, Inc. Blocking antibodies against CD47 and methods of use thereof
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
KR102587442B1 (ko) * 2018-08-31 2023-10-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 항-cd47 항체 또는 그 적용
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
JP2022521610A (ja) 2019-02-26 2022-04-11 ヤンセン バイオテツク，インコーポレーテツド 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化
CA3136450A1 (en) * 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Antibodies that target human cd47
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
MA56045A (fr) 2019-05-31 2022-04-06 Alx Oncology Inc Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire
JP2022535286A (ja) 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
GB2605276A (en) 2019-09-03 2022-09-28 Myeloid Therapeutics Inc Methods and compositions for genomic integration
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220103959A (ko) * 2019-10-25 2022-07-25 우시 바이올로직스 아일랜드 리미티드 신규한 항-cd47 항체 및 그 용도
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
US20240016787A1 (en) 2020-11-03 2024-01-18 Rdiscovery, LLC Methods for treatment of cancer and phagocytosis-deficiency related diseases
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124107A2 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3068506A (en) 1958-02-19 1962-12-18 Trico Products Corp Combined windshield cleaner and washer
US3068507A (en) 1959-08-28 1962-12-18 Babcock & Wilcox Ltd Fluid heater cleaners
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
KR100252547B1 (ko) 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69331089T2 (de) 1992-02-18 2002-07-18 Otsuka Kagaku Kk Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
WO2002033073A1 (fr) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agoniste degrade
EP1693385A4 (en) * 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
PL1885399T3 (pl) * 2005-05-26 2011-04-29 Seattle Genetics Inc Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
EP2231904B1 (en) 2007-12-19 2016-01-13 Janssen Biotech, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
EA201890907A1 (ru) 2009-11-30 2020-04-30 Янссен Байотек, Инк. МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
DK3789038T3 (da) * 2010-05-14 2022-10-17 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer mod cd47
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
PT2812443T (pt) 2012-02-06 2019-09-05 Inhibrx Inc Anticorpos cd47 e métodos de utilização dos mesmos
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
WO2014121093A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP4137518A1 (en) * 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL252198A0 (en) 2017-07-31
CN107406503A (zh) 2017-11-28
EP3221358B1 (en) 2021-07-21
CA2967379A1 (en) 2016-05-26
ZA201704117B (en) 2019-09-25
JP6857603B2 (ja) 2021-04-14
AU2015350190B2 (en) 2021-08-05
EA201791093A1 (ru) 2018-04-30
US10864268B2 (en) 2020-12-15
PH12017500915A1 (en) 2017-11-20
JP2018502060A (ja) 2018-01-25
CN107406503B (zh) 2021-07-16
MX2017006485A (es) 2018-03-23
AU2015350190A1 (en) 2017-06-01
US20180250395A1 (en) 2018-09-06
WO2016081423A1 (en) 2016-05-26
EP3221358A1 (en) 2017-09-27
SG11201704058TA (en) 2017-06-29
KR20170081699A (ko) 2017-07-12

Similar Documents

Publication Publication Date Title
BR112017010303A2 (pt) anticorpos anti-cd47, métodos e usos
CL2016002455A1 (es) Anticuerpos multiespecíficos.
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
NI201700167A (es) Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
EA201890441A1 (ru) Моноклональные антитела против bcma
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
CR20170079A (es) Agentes de unión a cd123 y usos de estos
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2016001154A1 (es) Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
CL2017001227A1 (es) Ganado lechero híbrido y sistemas para maximizar la ventaja híbrida.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CL2015002827A1 (es) Tratamientos de corrientes de relave.
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
CL2016001147A1 (es) Anticuerpos específicos para fcrn.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201301090A1 (ru) Антидоты антикоагулянтов
AR102469A1 (es) Bicicleta de cartón

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]